Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced expanded clinical use of its clonoSEQ measurable residual disease (MRD) test at the 67th ASH Annual Meeting, Dec 6–9, 2025 in Orlando.

Key highlights: 90 abstracts feature clonoSEQ data, including 17 showing MRD-guided clinical interventions. The phase II EndRAD study reported that 51 NGS MRD-negative B-ALL patients receiving non-TBI transplant conditioning had outstanding event-free and overall survival comparable to standard TBI approaches. Additional data include 200-patient AURIGA MRD dynamics, intensified maintenance doubling MRD-negativity, and an 80-patient CLL cohort showing deep remissions at a 10^-6 MRD threshold.

Positive

• 90 abstracts at ASH feature clonoSEQ data
• 17 abstracts demonstrate MRD-guided clinical interventions
• EndRAD: 51 NGS MRD-negative B-ALL patients showed outstanding EFS and OS with non-TBI conditioning
• AURIGA: 200 newly diagnosed MM patients showed deep MRD responses linked to longer PFS
• Intensified maintenance doubled MRD-negativity rates in post-transplant MM
• Phase II CLL: 80 patients achieved deep, durable remissions at a 10^-6 MRD threshold

Negative

• None.

Key Figures

ASH abstracts with clonoSEQ 90 abstracts Featuring clonoSEQ MRD data at 67th ASH Annual Meeting

Interventional clonoSEQ use 17 abstracts Abstracts where clonoSEQ MRD guided clinical actions

EndRAD non-TBI cohort size 51 patients NGS MRD-negative B-ALL patients receiving non-TBI regimens

Multiple Myeloma abstracts 32 abstracts 31 MM and 1 smoldering MM using clonoSEQ MRD

AURIGA study size 200 patients Newly diagnosed MM patients in phase III AURIGA trial

NHL abstracts 15 abstracts Non-Hodgkin lymphoma studies using clonoSEQ MRD

CLL abstracts 7 abstracts CLL studies leveraging clonoSEQ MRD

PVO CLL study size 80 patients Previously untreated CLL treated with pirtobrutinib, venetoclax, obinutuzumab

Market Reality Check

$14.75 Last Close

Volume Volume 7103535 is 2.55x the 20-day average of 2783459, indicating elevated trading activity ahead of the ASH news. high

Technical Price 14.75 is trading above the 200-day MA at 11.63, reflecting a longer-term uptrend despite the latest pullback.

Peers on Argus 1 Down

ADPT fell 14.79% while close peers showed mixed, mostly modest moves (e.g., AGIO +0.62%, GLPG -0.75%, IDYA -0.36%, TVTX -0.91%). Only IDYA appeared in momentum scans with a -5.19% move, underscoring ADPT’s decline as company-specific rather than a broad biotech move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 24	ASH MRD abstracts	Positive	+9.9%	Large ASH presence with 89 clonoSEQ abstracts and 36 oral talks.
Nov 06	Investor conferences	Neutral	-5.0%	Participation in Jefferies and Piper Sandler healthcare conferences.
Nov 05	Q3 2025 earnings	Positive	+4.0%	Strong MRD revenue growth, clonoSEQ volume gains, raised MRD guidance.
Oct 15	Earnings announcement date	Neutral	+0.9%	Scheduled Q3 earnings call and webcast timing details.
Aug 27	Conference participation	Neutral	+2.6%	Planned appearance at Morgan Stanley Global Healthcare Conference.

Pattern Detected

News tied to MRD and financial performance has often coincided with positive moves, while conference-only updates show mixed or divergent reactions.

Recent Company History

Over the last six months, Adaptive Biotechnologies highlighted expanding clonoSEQ MRD adoption and improving financials. On Nov 24, news of 89 ASH abstracts, including 36 orals, preceded a +9.94% move. Q3 results on Nov 5 showed revenue of $94.0M with MRD revenue of $56.8M and clonoSEQ volume of 27,111 tests, and the stock gained 3.96%. By contrast, several conference participation notices in August–November produced smaller, sometimes opposite, price reactions, suggesting investors respond more strongly to concrete MRD and earnings milestones than to event logistics.

Market Pulse Summary

This announcement underscores Adaptive’s focus on expanding clonoSEQ MRD as a decision-making tool, with 90 ASH abstracts and interventional use in 17 studies across MM, NHL, CLL and ALL. Data from trials such as AURIGA and EndRAD highlight links between deep MRD responses and survival outcomes. In context of earlier Q3 results showing MRD growth and raised guidance, investors may monitor how real-world adoption, updated guidelines, and additional clinical readouts reinforce or challenge clonoSEQ’s positioning in blood cancer care.

Key Terms

measurable residual disease medical

"exemplify how next-generation sequencing-based measurable residual disease (MRD) status is guiding"

Measurable residual disease (MRD) is the tiny number of cancer cells that remain in a patient after treatment and can be detected using sensitive laboratory tests even when scans look clear. For investors, MRD matters because it's a strong early signal of how well a therapy works, can influence clinical trial success, regulatory decisions and future sales, and helps predict whether disease will come back much like spotting embers after a put-out fire.

next-generation sequencing medical

"exemplify how next-generation sequencing-based measurable residual disease (MRD) status"

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

ctDNA medical

"Additionally, data supporting the integration of ctDNA into post–CAR T surveillance"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

progression free survival medical

"sustained MRD negativity correlated with improved progression free survival"

Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.

AI-generated analysis. Not financial advice.

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of its clonoSEQ^® test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6–9, 2025, in Orlando. Notably, 17 abstracts utilizing Adaptive’s clonoSEQ^® test exemplify how next-generation sequencing-based measurable residual disease (MRD) status is guiding clinical actions to improve blood cancer patient care.

Practice-changing data from the phase II EndRAD study support the use of NGS MRD status prior to allogeneic hematopoietic cell transplantation (HCT) to guide the selection of non-total body irradiation (TBI) conditioning approaches to reduce long-term toxicities in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL), without compromising outcomes. The study showed outstanding event-free and overall survival outcomes in 51 patients who were NGS MRD negative and received a non-TBI regimen. The study also enrolled a comparator cohort who received TBI and showed equivalent survival in NGS MRD negative patients who received TBI (the current standard of care) compared to non-TBI approaches (oral presentation, abstract 163).

“For young people facing leukemia, the impact of treatment doesn’t end when therapy does,” said Michael Pulsipher, M.D., Division Chief of Hematology, Oncology and Bone Marrow Transplantation at Primary Children’s Hospital and Huntsman Cancer Institute at the University of Utah. “The EndRAD results demonstrate that, for NGS MRD-negative patients, we may be able to choose transplant approaches without radiation that support both survival and long-term well-being—an advancement with real, lasting impact for patients and their families.”

Across hematologic malignancies, clonoSEQ MRD status is used by health care providers as an interventional tool to guide clinical decisions at key points in care. The presentations below show how investigators are applying clonoSEQ MRD results to tailor treatment intensity or duration with greater precision.

Multiple Myeloma (MM)

• A total of 32 abstracts will be presented (31 MM, one smoldering MM), with a focus on MRD assessment of treatment response, real-world data demonstrating the link between MRD status and clinical outcomes, and several studies describing how clonoSEQ MRD results are being used to guide treatment decisions.
• A presentation focused on MRD dynamics in the phase III AURIGA study of 200 newly diagnosed MM patients demonstrated that deep MRD responses and sustained MRD negativity correlated with improved progression free survival. The study shows that use of intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates (oral presentation, abstract 97).

Non-Hodgkin Lymphoma (NHL)

• Fifteen abstracts in NHL will be presented, focusing on use of MRD to better understand depth of response and to guide therapy.
• In diffuse large B-cell lymphoma (DLBCL), results from a phase II Wisconsin Oncology Network study which used clonoSEQ to de-escalate therapy in frail older adults with DLBCL will be presented (poster presentation, abstract 1964). Additionally, data supporting the integration of ctDNA into post–CAR T surveillance will be presented (oral presentation, abstract 941).
• Results from a phase II, MRD-guided study in older mantle cell lymphoma (MCL) patients demonstrate the use of clonoSEQ to guide duration of frontline BOVen therapy (zanubrutinib, obinutuzumab, venetoclax) (oral presentation, abstract 888).
  

Chronic Lymphocytic Leukemia (CLL)

• Seven abstracts utilizing clonoSEQ MRD will be presented, with the majority leveraging the test to assess treatment response and guide treatment discontinuation.
• Data from a Phase II study of 80 patients with previously untreated CLL showed that time-limited pirtobrutinib, venetoclax, and obinutuzumab (PVO) achieved notably deep and durable remissions based on MRD assessment at a threshold of 10^-6. MRD positive status using clonoSEQ was used to identify patients who may continue therapy, highlighting clonoSEQ as a potential tool for guiding treatment duration in this regimen (oral presentation, abstract 680).

Acute Lymphoblastic Leukemia (ALL)

• In addition to the EndRAD trial, 30 ALL abstracts will be presented describing the use of clonoSEQ to assess treatment response in investigator studies and real-world data, as well as analyses describing comparisons of bone marrow and peripheral blood MRD by clonoSEQ.
  

“The unprecedented volume and diversity of data at ASH this year further solidifies clonoSEQ’s leadership in the field of blood cancer MRD monitoring,” said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. “Our unmatched body of clinical evidence and real-world patient experience, together with meaningful updates across lymphoid cancer clinical practice guidelines over the past year, reflect clear recognition of the test’s value in accelerating therapeutic progress and strengthening MRD-informed patient management.”

About clonoSEQ^®
clonoSEQ^® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.

clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.

clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com

FAQ

What did Adaptive Biotechnologies (ADPT) present at ASH Dec 6–9, 2025?

Adaptive reported 90 abstracts with clonoSEQ data, including 17 showing MRD-informed treatment interventions.

What are the EndRAD phase II results for ADPT clonoSEQ in B-ALL?

EndRAD showed 51 NGS MRD-negative patients had outstanding event-free and overall survival with non-TBI conditioning, comparable to TBI.

How is clonoSEQ being used to guide multiple myeloma (ADPT) treatment?

In AURIGA (n=200), deep and sustained MRD negativity correlated with improved PFS and intensified maintenance doubled MRD-negativity rates.

Can clonoSEQ MRD guide treatment duration in CLL for ADPT?

Yes—an 80-patient Phase II study reported deep, durable remissions at a 10^-6 MRD threshold, using MRD positivity to identify patients who may continue therapy.

How many ASH abstracts use clonoSEQ for interventional decisions involving ADPT data?

17 abstracts specifically describe clonoSEQ MRD status guiding clinical actions or treatment selection.